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(0.2-39.3 cc). Low SRS dose was justified by larger volume, clinical 
history and critical anatomical location. Fixation was performed with 
a 3D-Line invasive frame, and all the patients underwent 
Angiography/CT/MR fusion for the localization of the target and the 
organ at risk. SRS was performed with 6 MV LINAC and MMLC of 3 mm. 
The radiation treatment was administered generally using five 
noncoplanar arcs with a single isocenter.  
Results: All the patients completed the SRS procedure without 
toxicity. Follow-up RM revealed complete obliteration of all AVM nidus 
in 7 out of 22 patients (32%) after 19 months of median follow up 
(range 12- 36).Complete response was seen only when 20 Gy were 
administered. After 12 months of follow up RM documented partial 
obliteration in 3 patients (13%) treated with 16 Gy. Median 15 months 
RM (3-24 months) showed persistent AVM nidus in 12 out of 22 patients 
(55%). 
Conclusions: In our series good response rate was seen in higher dose 
SRS (20 Gy) group. Low dose SRS is an effective and relatively safe 
mean of treating large, complex AVMs that are not suitable to surgery 
or higher dose SRS; obliteration rates for larger AVM are less than for 
small AVM according with literature data. AVM shunt regresses slowly 
over time so overall obliteration rates are further probably limited by 
shorter gap between SRS and radiological check.  
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Purpose/Objective: Our aim is to report the outcome of fractionated 
stereotactic radiationtherapy in the management of optic nerve 
sheath meningiomas.  
Materials and Methods: Between March 2007 and September 2010 a 
total of nine patients with primary benign optic nerve sheath 
meningioma (ONSM) have been treated with fractioned stereotactic 
radiotherapy (FSRT). One patient, from who there was no follow up 
available, was excluded. Results of these patients were analysed in a 
retrospective single centre study.  
Results: After a median follow up of 32 months (range 15-55) growth 
control on MRI was achieved in all 8 patients (100%), and reduction in 
tumour volume in 2 of these patients (25%). A total of 4 patients 
showed improvement of their visual acuity of at least two lines on the 
Snellen chart. A stabilization of vision was seen in 3 patients. 1 
patient was already blind before radiotherapy. Five patients had a 
stable visual field during follow up, 1 patient had an improved visual 
field and 1 patient had a deterioration of the visual field. Pre-existing 
clinical symptoms improved or even disappeared in all patients. Acute 
toxicity was mild and included transient headache in 2 patients, 
transient orbital pain in 2 patients and edema in 2 patients. 
Conclusions: In our series we achieved stable disease and stabilisation 
or improvement of visual acuity in all 8 treated patients. Fractionated 
stereotactic radiotherapy is an effective and save treatment option in 
patients with optic nerve sheath meningiomas. 
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Purpose/Objective: Management of recurrent Glioblastoma 
Multiforme (GBM) following definitive surgical resection, standard 
post-operative radiation therapy and temozolomide is challenging. 
This study analyzes the efficacy and morbidity associated with 
fractionated stereotactic radiotherapy (fSRT) for recurrent GBM.  
Materials and Methods: From September 2007 to December 2010, 17 
patients diagnosed with recurrent GBM after prior treatment with 
total resection followed by post-operative radiation (60Gy) and 
temozolomide were treated via re-irradiation using fSRT (including 
robotic assisted linear accelerator based fSRT and Cyberknife based 
fSRT). In all cases, recurrence was noted within the high-dose 
radiation therapy portal. Treatment consisted of a cumulative dose of 
2500cGy via 500cGy fractions prescribed to the D95 of the PTV 
(defined as GTV + 3mm).  
Results: Of the 17 patients treated, a radiographic response was 
observed in 8 (47%), while persistent tumor progression was noted in 9 
(53%). Median survival was 11.2 months for all patients, while median 
survival was 15.1 months in patients experiencing a radiographic 
response. Toxicity included limited alopecia and minor fatigue.  
Conclusions: Although the clinical management of recurrent GBM is 
challenging, the present data demonstrates significant salvage rates 
with acceptable morbidity. Fractionated SRT provides a viable 
alternative to other potential treatment options including re-resection 
and systemic therapy.  
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Purpose/Objective: Linac-based stereotactic radiotherapy (SRT) has 
been employed in the Department of Radiation Oncology, of European 
Institute of Oncology, EIO, Milan, Italy since 3/2003 and more than 
400 patients (pts) have been treated so far for brain metastases. In 
12/2011 CyberKnife Unit was installed in EIO. The objective of this 
study is to evaluate feasibility and acute toxicity profile of CBK-SRT 
for brain metastases in the first 8 months of clinical activity of the EIO 
CyberKnife. 
Materials and Methods: Inclusion criteria: for this retrospective study 
were as follows: 1) adult patients; 2) with up to 3 brain metastases 
(mets); 3) that underwent CBK-SRT at EIO between 12/2011 and 
10/2012 and 4) gave written informed consent for the treatment. 
Previous radiotherapy or concomitant systemic therapy was allowed. 
Treatment protocol: Contouring was based on the computer 
tomography (CT) and contrast medium magnetic resonance (MR). 
Treatments planning was performed using a MultiPlan® 4.5 treatment 
planning system (Accuray, Inc.). Sequential Optimization inverse 
planning algorithm was used: treatment plan typically involved 100-
200 beams, using 1-3 fixed circular collimators, which ranged in size 
from 5-60 mm. 6D skull tracking was used for intracranial lesions. It 
was based on rigid body registration of bony landmarks of the 
patient’s head to track intracranial targets and automatically correct 
for the translational or rotational shift that occurs during the 
treatment. Clinical monitoring: CBK-SRT was performed on the out-
patient basis. Steroid premedication was administrated. The toxicity 
was evaluated with use of Radiation Therapy Oncology 
Group/European Organization for Research and Treatment of Cancer 
(RTOG/EORTC) criteria. 
Results: Between 12/2011 and 10/2012 consecutive 85 pts were 
treated: primary diagnosis included lung (38 pts), breast (29 pts) and 
other malignancies (18 pts). Median age was 60 years (range, 37-82 
years). In all pts single brain metastasis was treated, while in 16, 4 
and 1 pts – 2, 3 and 4 lesions were treated, respectively (in 1 pt 
lesions were treated metachronously). CBK-SRT consisted in first 
radiotherapy and re-irradiation in case of 78 (92%) and 7 lesions, 
respectively. Median CBK-SRT dose was 20 Gy (range, 8-25 Gy)/1 
fraction (range, 1-5 fractions). All patients completed planned CBK-
SRT and no acute toxic event was registered. 
Conclusions: CyberKnife-based SRT is a feasible approach for limited 
brain metastatic disease offering short and well accepted treatment 
with low toxicity profile. Further investigation is warranted in order to 
evaluate the tumor control and late toxicity. The optimal combination 
with systemic treatment or surgery should also be defined.  
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Purpose/Objective: Stereotactic ablative body radiotherapy (SBRT, 
SABR) is being increasingly applied because of its high local efficacy, 
for small lung tumors and oligometastatic patients (pts). However, the 
optimum dosage is still under discussion. Here, we report data on 30 
lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 26 
patients, as part of a dose escalation study program, treated between 
2007 and 2011 by TomoTherapy SBRT. 
Materials and Methods: SBRT was performed with total doses of 54 Gy 
in 6 fractions. Eight pts were affected by stage I NSCLC, 18 were pts 
with oligo-recurrence cancer in the lung. Median age was 69.7 yrs (45-
91). In each patient a planning 18FDG-PET/CT was acquired in 4D-
mode to define a personalized ITV as a GTVs sum and the PTV with 
appropriate ITV expansions. Before each fraction a Mega-Voltage CT 
(MV-CT) was acquired for patient repositioning. Three-monthly follow-
up CT scans were supplemented by FDG-PET/CT if clinically indicated. 
Results: The median follow-up period was 22 months (range, 2-46 
months). Local progression-free survival rates was 70%, Overall 
survival rates was 96%. 21 and 20 pts had G0 acute and late toxicity, 
while 5 and 6 patients experienced respectively acute and late G1 
